“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Progressing towards the development of biosimilar products
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
Lupin’s Europe business recorded a growth of 2% with sales of Rs.5,498 million during the year. As part of our strategic vision, we have a strong focus on building a Specialty products portfolio while continuing to grow our Generics business in the region. On the Generic side, we continue to build on a meaningful portfolio of niche products while extending and deepening the relationships with our strategic partners within Europe. Our Specialty play in the Neurology space for the European region, together with our strong pipeline in Complex Generics, Biosimilars and Inhalation will further enhance the value of our business.
We have filed three marketing authorization applications with the EU Authorities, having received two approvals (including NaMuscla) during FY2019. At present, the cumulative filings for Europe stand at 60 with 56 approvals to date.
